NewsRamp is a PR & Newswire Technology platform that enhances press release distribution by adapting content to align with how and where audiences consume information. Recognizing that most internet activity occurs outside of search, NewsRamp improves content discovery by programmatically curating press releases into multiple unique formats—news articles, blog posts, persona-based TLDRs, videos, audio, and Zero-Click content—and distributing this content through a network of news sites, blogs, forums, podcasts, video platforms, newsletters, and social media.
FAQ: Sigyn Therapeutics' CardioDialysis™ and Nature Publication on Cardiovascular Disease in Dialysis Patients
TL;DR
Sigyn Therapeutics' CardioDialysis offers a competitive edge by targeting a $100 billion market with a broad-spectrum therapy that reduces MACE more effectively than single-target drugs.
CardioDialysis works by reducing inflammatory molecules and cholesterol-transporting lipoproteins during dialysis treatments, leveraging existing dialysis machine infrastructure for deployment.
This therapy could significantly improve and extend the lives of ESRD patients by addressing their unique cardiovascular risks during regular dialysis sessions.
CardioDialysis transforms kidney dialysis clinics into cardiovascular treatment centers using existing equipment to combat a leading cause of death worldwide.
Found this article helpful?
Share it with your network and spread the knowledge!
The note discusses how a recent Nature publication reinforces the company's rationale for its CardioDialysis™ therapy, which aims to address cardiovascular disease in end-stage renal disease (ESRD) patients undergoing dialysis.
ESRD dialysis patients have up to a 20-fold greater risk of death from cardiovascular disease compared to the general population, and existing cardiovascular drugs have not improved survival or reduced cardiovascular events in this patient group.
CardioDialysis™ is a non-pharmacological, dialysis-like therapy that aims to reduce circulating inflammatory molecules that fuel cardiovascular disease while simultaneously lowering cholesterol-transporting lipoproteins that contribute to heart attacks, strokes, and other Major Adverse Cardiovascular Events (MACE).
While the Nature article authors suggest future drug studies should focus on specific inflammatory targets, CardioDialysis™ takes a broad-spectrum approach by addressing multiple inflammatory molecules and lipoproteins simultaneously, and it performs functions beyond the reach of drugs.
CardioDialysis™ provides a non-pharmacological option for patients unresponsive to cholesterol-lowering drugs, enhances the benefit of cardiovascular drugs without adding further drug toxicity, and can be conveniently administered during regularly scheduled dialysis treatments.
The initial clinical and commercialization focus is directed toward end-stage renal disease (ESRD) patients undergoing dialysis, who face significantly elevated cardiovascular disease risk.
The Nature review article was published on November 20, 2025, and the CEO note referencing it was released on December 3, 2025.
The annual market for MACE-reducing therapies is reported to exceed $100 billion, positioning CardioDialysis™ to address a significant commercial opportunity.
The Nature review article can be accessed at: https://www.nature.com/articles/s41581-025-01035-z
Readers are encouraged to continue reading the content below the CEO note for more information about CardioDialysis™, though no specific contact information is provided in this excerpt.
Curated from NewMediaWire
